Anxiety is highly prevalent in Alzheimer's disease (AD), correlating with cerebrospinal fluid/positron emission tomography biomarkers and disease progression. Relationships to plasma biomarkers are unclear. Herein, we compare levels of plasma biomarkers in research participants with and without anxiety at cognitively normal, mild cognitive impairment, and AD dementia stages. We observed significantly higher plasma tau/amyloid-β42 ratio in AD participants with anxiety versus those without, but did not observe differences at other stages or plasma biomarkers. No such relationships were evident with depression. These results support a unique pathophysiological relationship between anxiety and AD that can be reflected in plasma biomarkers, suggestive of heightened neurodegeneration.
FinkelSICosta e SilvaJCohenG, et al.Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr1997; 8: 497–500.
2.
SpallettaGMusiccoMPadovaniA, et al.Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry2010; 18: 1026–1035.
3.
NgKPChiewHRosa-NetoP, et al.Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Transl Neurodegener2021; 10: 11.
4.
TaraganoFEAllegriRFKrupitzkiH, et al.Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry2009; 70: 584–592.
5.
IsmailZSmithEEGedaY, et al.Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement2016; 12: 195–202.
6.
IsmailZAgüera-OrtizLBrodatyH, et al.The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis2017; 56: 929–938.
7.
IsmailZGatchelJBatemanDR, et al.Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria. Int Psychogeriatr2018; 30: 185–196.
8.
PatelPMasurkarAV. The relationship of anxiety with Alzheimer's disease: a narrative review. Curr Alzheimer Res2021; 18: 359–371.
9.
HuangLHuangQXieF, et al.Neuropsychiatric symptoms in Alzheimer's continuum and their association with plasma biomarkers. J Affect Disorders2024; 348: 200–206.
10.
Krell-RoeschJZanilettiISyrjanenJA, et al.Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: a community-based study. Alzheimers Dement (Amst)2023; 15: e12461.
11.
OvodVRamseyKNMawuenyegaKG, et al.Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement2017; 13: 841–849.
12.
NakamuraAKanekoNVillemagneVL, et al.High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature2018; 554: 249–254.
13.
KauferDICummingsJLKetchelP, et al.Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci2000; 12: 233–239.
14.
BabulalGMGhoshalNHeadD, et al.Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry2016; 24: 1095–1104.
15.
BanningLCPRamakersIHGBKöhlerS, et al.The association between biomarkers and neuropsychiatric symptoms across the Alzheimer's disease spectrum. Am J Geriatr Psychiatry2020; 28: 735–744.
16.
OlssonBLautnerRAndreassonU, et al.CSF And blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol2016; 15: 673–684.
17.
PalmerKBergerAKMonasteroR, et al.Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology2007; 68: 1596–1602.
18.
WadsworthLPLoriusNDonovanNJ, et al.Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord2012; 34: 96–111.
19.
MahLBinnsMASteffensDC. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry2015; 23: 466–476.
20.
ParkJ-CHanS-HYiD, et al.Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease. Brain2019; 142: 771–786.
21.
BanningLCPRamakersIHGBDeckersK, et al.Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: a systematic literature review. Neurosci Biobehav Rev2019; 107: 346–359.
22.
DevierDJPeltonGHTabertMH, et al.The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease. Int J Geriatr Psychiatry2009; 24: 1335–1342.
23.
BarnesLLBennettDA. Alzheimer’s disease in African Americans: risk factors and challenges for the future. Health Affairs2014; 33: 580–586.
24.
DenizKHoCCGMalphrusKG, et al.Plasma biomarkers of Alzheimer's disease in African Americans. J Alzheimers Dis2021; 79: 323–334.
25.
MorrisJCSchindlerSEMcCueLM, et al.Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol2019; 76: 264–273.
26.
BurkeSLCadetTAlcideA, et al.Psychosocial risk factors and Alzheimer's disease: the associative effect of depression, sleep disturbance, and anxiety. Aging Mental Health2018; 22: 1577–1584.
27.
MatthewsKAXuWGagliotiAH, et al.Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dement2019; 15: 17–24.
28.
RajanKBWeuveJBarnesLL, et al.Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060). Alzheimers Dement2021; 17: 1966–1975.
29.
DennyAStreitzMStockK, et al.Perspective on the “African American participation in Alzheimer disease research: effective strategies” workshop, 2018. Alzheimers Dement2020; 16: 1734–1744.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
